Eosinophilic Myocarditis in a Patient With Multiple Myeloma.
暂无分享,去创建一个
[1] L. Potena,et al. Fulminant Versus Acute Nonfulminant Myocarditis in Patients With Left Ventricular Systolic Dysfunction. , 2019, Journal of the American College of Cardiology.
[2] T. Dardas,et al. FROM MULTIPLE MYELOMA TO MYOCARDITIS , 2019, Journal of the American College of Cardiology.
[3] Uzair Yaqoob,et al. The Clinicopathological Profile of Eosinophilic Myocarditis , 2018, Cureus.
[4] Jaeho Bae,et al. The combination of ionizing radiation and proteasomal inhibition by bortezomib enhances the expression of NKG2D ligands in multiple myeloma cells , 2018, Journal of radiation research.
[5] K. Klingel,et al. Eosinophilic Myocarditis: Characteristics, Treatment, and Outcomes. , 2017, Journal of the American College of Cardiology.
[6] S. Phillips,et al. Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma , 2017, Cardio-Oncology.
[7] E. Hatzimichael,et al. “Real-world” data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group , 2013, Annals of Hematology.
[8] M. Krause,et al. Radiotherapy and "new" drugs-new side effects? , 2011, Radiation oncology.
[9] J. Carver,et al. Myocarditis During Lenalidomide Therapy , 2010, The Annals of pharmacotherapy.
[10] P. Wen,et al. A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. , 2009, International journal of radiation oncology, biology, physics.
[11] F. Meyer,et al. Dysregulation of the Ubiquitin-Proteasome System in Human Carotid Atherosclerosis , 2006, Arteriosclerosis, thrombosis, and vascular biology.